BL-1020, a new γ-aminobutyric acid-enhanced antipsychotic: Results of 6-week, randomized, double-blind, controlled, efficacy and safety study

Keyphrases

• Efficacy Study 100%
• Antipsychotics 100%
• Safety Study 100%
• Aminobutyric Acid 100%
• Risperidone 100%
• Randomized Double-blind Study 100%
• Placebo 75%
• No Significant Difference 50%
• Negative Syndrome 50%
• Brief Assessment of Cognition in Schizophrenia 50%
• Extrapyramidal Symptoms 50%
• Symptom Score 50%
• Clinical Global Impressions Scale 50%
• United States 25%
• India 25%
• Randomized Controlled Trial 25%
• Cognitive Impairment 25%
• DSM-IV-TR 25%
• Schizophrenic 25%
• Cognitive Functioning 25%
• U.S. Food 25%
• Hospital-based 25%
• Psychotic Symptoms 25%
• Trial Registration 25%
• Composite Score 25%
• Psychiatric Patients 25%
• Romania 25%
• Placebo Effect 25%
• Chronic Schizophrenia 25%
• GABA Agonist 25%
• Agonist Activity 25%
• Treatment Research 25%
• Randomized Double-blind 25%
• Safety Profile 25%
• Dopamine Antagonism 25%
• Acutely Ill Patients 25%
• Cognitive Effects 25%
• Cognitive Test Battery 25%
• Cognition in Schizophrenia 25%
• Readiness for Hospital Discharge 25%
• Mg Effect 25%
• Research to Improve 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Risperidone 100%
• Antipsychotic 100%
• 4 Aminobutyric Acid 100%
• Placebo 100%
• Schizophrenia 100%
• Positive Syndrome 50%
• Negative Syndrome 50%
• Extrapyramidal Symptoms 50%
• Randomized Controlled Trial 25%
• 4 Aminobutyric Acid Receptor Stimulating Agent 25%
• Cognitive Defect 25%
• DSM-IV-TR 25%
• Dopamine 25%

Neuroscience

• Risperidone 100%
• Gamma-Aminobutyric Acid 100%
• Placebo 100%
• Antipsychotic 100%
• Schizophrenia 100%
• Negative Syndrome 50%
• Positive Syndrome 50%
• Extrapyramidal Symptoms 50%
• Dopamine 25%
• Cognitive Disorders 25%
• Randomized Controlled Trial 25%
• GABA Agonist 25%